Citigroup’s Abeona Therapeutics ABEO Stock Holding History
Bought
Maintained
Sold
Other funds holding ABEO
NCM
CCC
ACM
OIA
AIC
KCM
Citigroup's ABEO Position: Q2 2026 in Review
Citigroup increased its Abeona Therapeutics (ABEO) stake by 4.9% in Q2 2026, buying an estimated $142K and bringing the position to 548,300 shares worth $3.39M. The position accounts for ﹤0.01% of the portfolio, ranked #2487.
Citigroup first reported a position in ABEO in Q2 2015 and has held it in 37 quarters since. The position peaked at $3.9M in Q3 2024. 126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.
- Citigroup held 548,300 shares of Abeona Therapeutics worth $3.39M as of Q2 2026.
- Citigroup bought 25,855 Abeona Therapeutics shares in Q2 2026, an estimated $142K.
- Abeona Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2487 holding.
- Citigroup first reported a position in Abeona Therapeutics in Q2 2015 and has held it in 37 quarters since.
- Citigroup's Abeona Therapeutics position peaked at $3.9M in Q3 2024.
- 126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.